Developer docs
API playgroundTry for free, no card

Search company profiles

TissueGene

Full company profile

uuid0004q81

Namestring
TissueGene
Legal namestring
Kolon TissueGene, Inc.
Websiteurl
tissuegene.com
Company typeenum
Public
Founded yearint
1999
Descriptiontext

Kolon TissueGene, Inc. is a Maryland-headquartered, Delaware-incorporated clinical-stage biopharmaceutical company (KOSDAQ: 950160) developing allogeneic cell and gene therapies for musculoskeletal and degenerative orthopedic disorders. Its lead product TG-C (marketed ex-US as Invossa/Invossa-K Inj) is a first-in-class mixed-cell gene therapy that combines non-modified human chondrocytes with TGF-beta1-expressing kidney-derived 293 cells, delivered as a single intra-articular injection. The therapy is being developed for knee osteoarthritis (Phase 3 dosing complete across 1,066 patients in two pivotal US trials, with topline data expected July 2026 and BLA filing targeted for an anticipated 2027 approval), hip osteoarthritis (Phase 2), and degenerative disc disease of the spine (Phase 1). Earlier pipeline candidates include TG-B (bone), TG-D (disc), and TG-N (nerve).

The company's revenue mechanics are pre-commercial licensing and milestone-based rather than product-based. Asia (ex-Japan) rights are licensed to Kolon Life Science, a sister subsidiary of parent company Kolon Group, which received Korean MFDS marketing approval for Invossa-K Inj in July 2017. Japan rights are licensed to Mitsubishi Tanabe Pharma under a deal valued at approximately $24M upfront plus up to $410M in milestones plus double-digit royalties. Kolon TissueGene retains direct commercialization rights for the US, Europe, and South America, and is preparing for US launch with a Lonza commercial manufacturing partnership signed October 2024. Operating funding has been supported by a 2017 KOSDAQ offshore IPO, a $750,000 Maryland Stem Cell Research Fund grant, and consistent annual exempt securities offerings of approximately $30-35M.

The company is majority-owned by the Kolon Group, employs 11-50 people at its Rockville, Maryland headquarters, and is led by a Co-CEO structure (Moon Jong Noh, Sung Han, and Jeon Seung-ho, who joined March 2025 for US commercialization) with a 2026-reorganized board that added Merck/Keytruda and global biotech commercialization talent. Key clinical and regulatory milestones include a 2015 FDA Special Protocol Assessment, an April 2019 FDA Clinical Hold (lifted April 2020), a December 2021 FDA hip OA Phase 2 clearance, and a December 2023 FDA spine IND approval.

Short descriptiontext

Kolon TissueGene is a clinical-stage biopharmaceutical company developing first-in-class allogeneic cell and gene therapies, led by TG-C for knee osteoarthritis, for patients with musculoskeletal and degenerative orthopedic disorders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell and gene therapy, regenerative medicine, osteoarthritis treatment, orthopedic biopharmaceuticals, allogeneic cell therapy
Industry3 codes
PRIMARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Cell and Gene Therapy
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales (US, Europe, South America)
TypeOne Time License
Description

Direct commercialization of TG-C in markets where Kolon TissueGene retains full rights. The company is preparing for BLA submission to FDA with anticipated approval in 2027.

tissuegene.com
2Licensing Royalties (Asia)
TypeLicensing Royalties
Description

Kolon Life Science holds exclusive rights for Asia (excluding certain regions). Mitsubishi Tanabe has exclusive rights for Japan with upfront payment of $24M plus up to $410M in milestones and double-digit sales royalties.

tissuegene.com
3Milestone Payments
TypeLicensing Royalties
Description

Achievement-based payments from licensing partnerships including development, regulatory, and commercial milestones. Kolon Life Science partnership with Mitsubishi Tanabe includes up to approximately $434M in total potential payments.

koreatimes.co.kr
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Invossa
Description

World's first cell and gene therapy for knee osteoarthritis, also known as TG-C (TissueGene-C). An allogeneic cell therapy involving human chondrocytes genetically modified to produce TGF-beta1.

tissuegene.com
Core offering1 text field

TissueGene (Kolon TissueGene, Inc.) develops TG-C (TissueGene-C / Invossa), an allogeneic cell and gene therapy for osteoarthritis of the knee, administered as a single intra-articular injection. The therapy combines non-modified chondrocytes with gene-modified human cells (kidney-derived 293 cells) engineered to express TGF-beta1, aimed at cartilage regeneration, pain reduction, and disease progression delay. The company is also expanding TG-C into hip osteoarthritis and degenerative disc disease indications, with additional pipeline candidates (TG-B, TG-D, TG-N) for bone, disc, and nerve regeneration.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • VAS pain score reduction: -18.4 (BMI<30), -26.1 (BMI≥30) in Phase 2 trial
+4 more records
Product overview1 text field

TissueGene (Kolon TissueGene, Inc.) is a Maryland-based biopharmaceutical company developing advanced allogeneic cell and gene therapies for musculoskeletal and degenerative disorders. The core product is TG-C (TissueGene-C), an investigational first-in-class cell and gene therapy for osteoarthritis of the knee delivered as a single intra-articular injection. TG-C has completed Phase III dosing in the US and is pursuing DMOAD designation. The product is also being expanded into hip osteoarthritis (Phase II) and degenerative disc disease (Phase I). The company also holds earlier-stage pipeline candidates TG-B (bone), TG-D (disc), and TG-N (nerve). In Asia (Korea), the marketed version Invossa-K Inj received MFDS marketing approval in July 2017. The company operates through clinical operation partnerships with organizations including Medpace, Chondrometrics, Nordic Bioscience, Boston Imaging Core Lab, ClinMatrix, Medrio, SignantHealth, CLARIO, and Labcorp, and partners with Lonza for commercial manufacturing and Kolon Life Science for Asian commercialization.

Product and service5 records
1TG-C (TissueGene-C)
CategoryCell and Gene Therapy - Core Product
Description

An allogeneic cell and gene therapy for osteoarthritis of the knee, delivered as a single intra-articular injection. TG-C uses human chondrocytes (cartilage cells) genetically modified to produce TGF-beta1 for cartilage regeneration, reducing pain, improving function, and slowing disease progression. The therapy is designed to achieve DMOAD (Disease-Modifying Osteoarthritis Drug) designation from the FDA. Being expanded into hip osteoarthritis (Phase II) and degenerative disc disease (Phase I) indications.

2Invossa-K Inj (Invossa-K)
CategoryCell and Gene Therapy - Marketed Product (Asia)
Description

The marketed version of TG-C in South Korea, approved by the Korea Ministry of Food and Drug Safety (MFDS) in July 2017 for knee osteoarthritis. Commercialized by Kolon Life Science with marketing support from Mundipharma and Kolon Pharmaceuticals. Asia rights are licensed from Kolon TissueGene.

3TG-B (TissueGene-B)
CategoryCell and Gene Therapy - Pipeline Product (Bone Regeneration)
Description

A pipeline product candidate in TissueGene's portfolio for bone regeneration, part of the company's broader portfolio of cell therapy programs for orthopedic disease treatment alongside TG-C, TG-D, and TG-N.

4TG-D (TissueGene-D)
CategoryCell and Gene Therapy - Pipeline Product (Disc Regeneration)
Description

A pipeline product candidate in TissueGene's portfolio for disc regeneration, being developed for treatment of intervertebral disc disorders as part of the company's orthobiology portfolio of cell and gene therapies.

5TG-N (TissueGene-N)
CategoryCell and Gene Therapy - Pipeline Product (Nerve Regeneration)
Description

A pipeline product candidate in TissueGene's portfolio for nerve tissue regeneration, part of the company's four-product portfolio of cell-mediated therapies targeting various orthopedic diseases.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-10-01
Description

Commercial manufacturing partnership signed October 2024. Lonza, the world's largest pharmaceutical CDMO, will produce TG-C for commercial supply. Collaboration with Kolon Biologics (subsidiary of Kolon Life Science) for manufacturing.

2Kolon Life Science (Middle East Expansion)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-06-22
Description

Saudi Arabia and UAE added to license agreement with Kolon Life Science until 2024. Consideration for continued presence following FDA approval.

tissuegene.com
3Kolon Life Science
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-07-01
Description

Kolon Life Science (KOSDAQ: 102940), a subsidiary of Kolon Group, is the exclusive licensee for Asia commercialization of TG-C. Received Korean MFDS marketing approval in July 2017 for Invossa-K Inj. Also partnered with Mitsubishi Tanabe for Japanese market. Kolon Life Science is responsible for manufacturing activities in Asia.

tissuegene.com
4Mitsubishi Tanabe Pharma
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2016-11-01
Description

Exclusive licensing and development agreement for Japan market. Mitsubishi Tanabe paid approximately $24 million upfront plus up to $410 million in development, regulatory, and commercial milestones, plus double-digit sales royalties. Japan OA market forecast: 25 million+ patients aged 40+.

tissuegene.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2016-11-01
Description

Singapore-based Juniper Therapeutics entered technology transfer agreement with Kolon Life Science for Japan development and commercialization of TG-C in 2022.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Clinical operation network partner for Phase 3 clinical trials providing clinical trial management services.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Clinical operation network partner providing MRI analysis services for clinical trials.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Clinical operation network partner for biomarker analysis in clinical trials.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Clinical operation network partner for imaging core laboratory services.

10ClinMatrix
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Clinical operation network partner for clinical data management.

tissuegene.com
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Clinical operation network partner for pathology services.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Clinical operation network partner for endpoint adjudication services.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Clinical operation network partner for laboratory testing services in clinical trials.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Flexion Therapeutics
TypeDirect peer
Description

Developer of Zilretta (intra-articular extended-release corticosteroid) for knee osteoarthritis pain. Most direct US commercial-stage peer to TG-C, targeting the same orthopedic/rheumatology prescribers for knee OA pain management.

TypeDirect peer
Description

Orthobiologics company offering hyaluronic acid (Durolane, Supartz) and other joint-pain therapies. Directly competes in the knee OA intra-articular injection market with TG-C and shares the same orthopedic surgeon call point.

TypeDirect peer
Description

Developer of viscosupplementation products (Monovisc, Orthovisc, Cingal) for joint pain and early-stage regenerative cartilage repair programs. Same intra-articular OA injection category and similar specialty distribution model.

TypeDirect peer
Description

Commercial-stage cell-therapy company selling MACI (autologous cultured chondrocytes for cartilage repair). Closest US-listed peer in orthopedic regenerative cell therapy and shares TG-C's orthopedics/sports-medicine surgeon customer base.

TypeDirect peer
Description

Allogeneic mesenchymal stem cell therapy developer with remestemcel-L and pipeline programs targeting inflammatory/orthopedic indications. Comparable cell-therapy platform business model and similar regulatory pathway for biologics in musculoskeletal disease.

TypeBroad incumbent
Description

Global orthopedic devices leader with a significant orthobiologics franchise and joint-replacement franchise. Relevant incumbent competitor covering both the conservative-care (biologics) and surgical (TKA) ends of the knee OA treatment spectrum.

TypeBroad incumbent
Description

Major orthopedic reconstruction and sports medicine company with a broad portfolio including knee implants and orthobiologics. Represents the surgical alternative TG-C aims to delay, making it a critical incumbent context.

TypeBroad incumbent
Description

Global medical device company with sports medicine, orthobiologics (Regeneten, Arthroscopic HA products), and knee-reconstruction franchises. Overlaps with TG-C's orthopedic surgeon call point across the conservative-to-surgical spectrum.

9Seikagaku
TypeRegional player
Description

Japan-based specialty company focused on hyaluronic acid intra-articular injections (Artz, Supartz) for knee OA. Closest regional comparable in Japan given Kolon's Mitsubishi Tanabe partnership and shares the intra-articular OA injection modality.

TypeBroad incumbent
Description

Synvisc/ Synvisc-One is one of the most-prescribed HA intra-articular injections for knee OA globally, distributed through Genzyme/Sanofi's specialty channel. Represents the dominant incumbent therapy TG-C would displace in the same indication and same prescriber base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TissueGene

Cell and Gene Therapytissuegene.com

Kolon TissueGene is a clinical-stage biopharmaceutical company developing first-in-class allogeneic cell and gene therapies, led by TG-C for knee osteoarthritis, for patients with musculoskeletal and degenerative orthopedic disorders.

What TissueGene does

Kolon TissueGene, Inc. is a Maryland-headquartered, Delaware-incorporated clinical-stage biopharmaceutical company (KOSDAQ: 950160) developing allogeneic cell and gene therapies for musculoskeletal and degenerative orthopedic disorders. Its lead product TG-C (marketed ex-US as Invossa/Invossa-K Inj) is a first-in-class mixed-cell gene therapy that combines non-modified human chondrocytes with TGF-beta1-expressing kidney-derived 293 cells, delivered as a single intra-articular injection. The therapy is being developed for knee osteoarthritis (Phase 3 dosing complete across 1,066 patients in two pivotal US trials, with topline data expected July 2026 and BLA filing targeted for an anticipated 2027 approval), hip osteoarthritis (Phase 2), and degenerative disc disease of the spine (Phase 1). Earlier pipeline candidates include TG-B (bone), TG-D (disc), and TG-N (nerve).

The company's revenue mechanics are pre-commercial licensing and milestone-based rather than product-based. Asia (ex-Japan) rights are licensed to Kolon Life Science, a sister subsidiary of parent company Kolon Group, which received Korean MFDS marketing approval for Invossa-K Inj in July 2017. Japan rights are licensed to Mitsubishi Tanabe Pharma under a deal valued at approximately $24M upfront plus up to $410M in milestones plus double-digit royalties. Kolon TissueGene retains direct commercialization rights for the US, Europe, and South America, and is preparing for US launch with a Lonza commercial manufacturing partnership signed October 2024. Operating funding has been supported by a 2017 KOSDAQ offshore IPO, a $750,000 Maryland Stem Cell Research Fund grant, and consistent annual exempt securities offerings of approximately $30-35M.

The company is majority-owned by the Kolon Group, employs 11-50 people at its Rockville, Maryland headquarters, and is led by a Co-CEO structure (Moon Jong Noh, Sung Han, and Jeon Seung-ho, who joined March 2025 for US commercialization) with a 2026-reorganized board that added Merck/Keytruda and global biotech commercialization talent. Key clinical and regulatory milestones include a 2015 FDA Special Protocol Assessment, an April 2019 FDA Clinical Hold (lifted April 2020), a December 2021 FDA hip OA Phase 2 clearance, and a December 2023 FDA spine IND approval.

TissueGene firmographics

Firmographics
Name
TissueGene
Legal name
Kolon TissueGene, Inc.
Website
https://tissuegene.com
Company type
Public
Founded year
1999
Operating status
Operating
Headcount range
51–100 employees
Short description
Kolon TissueGene is a clinical-stage biopharmaceutical company developing first-in-class allogeneic cell and gene therapies, led by TG-C for knee osteoarthritis, for patients with musculoskeletal and degenerative orthopedic disorders.
Ownership category
akta.pro rank

TissueGene industry classification

Industry
Product category
Cell and Gene Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Cell and gene therapy
  • Regenerative medicine
  • Osteoarthritis treatment
  • Orthopedic biopharmaceuticals
  • Allogeneic cell therapy

Where TissueGene is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

TissueGene business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. Product Sales (US, Europe, South America): Direct commercialization of TG-C in markets where Kolon TissueGene retains full rights. The company is preparing for BLA submission to FDA with anticipated approval in 2027.
  2. Licensing Royalties (Asia): Kolon Life Science holds exclusive rights for Asia (excluding certain regions). Mitsubishi Tanabe has exclusive rights for Japan with upfront payment of $24M plus up to $410M in milestones and double-digit sales royalties.
  3. Milestone Payments: Achievement-based payments from licensing partnerships including development, regulatory, and commercial milestones. Kolon Life Science partnership with Mitsubishi Tanabe includes up to approximately $434M in total potential payments.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

TissueGene product offering

Product offering

Core offering

TissueGene (Kolon TissueGene, Inc.) develops TG-C (TissueGene-C / Invossa), an allogeneic cell and gene therapy for osteoarthritis of the knee, administered as a single intra-articular injection. The therapy combines non-modified chondrocytes with gene-modified human cells (kidney-derived 293 cells) engineered to express TGF-beta1, aimed at cartilage regeneration, pain reduction, and disease progression delay. The company is also expanding TG-C into hip osteoarthritis and degenerative disc disease indications, with additional pipeline candidates (TG-B, TG-D, TG-N) for bone, disc, and nerve regeneration.

Product overview

TissueGene (Kolon TissueGene, Inc.) is a Maryland-based biopharmaceutical company developing advanced allogeneic cell and gene therapies for musculoskeletal and degenerative disorders. The core product is TG-C (TissueGene-C), an investigational first-in-class cell and gene therapy for osteoarthritis of the knee delivered as a single intra-articular injection. TG-C has completed Phase III dosing in the US and is pursuing DMOAD designation. The product is also being expanded into hip osteoarthritis (Phase II) and degenerative disc disease (Phase I). The company also holds earlier-stage pipeline candidates TG-B (bone), TG-D (disc), and TG-N (nerve). In Asia (Korea), the marketed version Invossa-K Inj received MFDS marketing approval in July 2017. The company operates through clinical operation partnerships with organizations including Medpace, Chondrometrics, Nordic Bioscience, Boston Imaging Core Lab, ClinMatrix, Medrio, SignantHealth, CLARIO, and Labcorp, and partners with Lonza for commercial manufacturing and Kolon Life Science for Asian commercialization.

Differentiator

Problem solved

Functional benefit

Brands

  • Invossa: World's first cell and gene therapy for knee osteoarthritis, also known as TG-C (TissueGene-C). An allogeneic cell therapy involving human chondrocytes genetically modified to produce TGF-beta1.

Products and services

  • TG-C (TissueGene-C) An allogeneic cell and gene therapy for osteoarthritis of the knee, delivered as a single intra-articular injection. TG-C uses human chondrocytes (cartilage cells) genetically modified to produce TGF-beta1 for cartilage regeneration, reducing pain, improving function, and slowing disease progression. The therapy is designed to achieve DMOAD (Disease-Modifying Osteoarthritis Drug) designation from the FDA. Being expanded into hip osteoarthritis (Phase II) and degenerative disc disease (Phase I) indications.
  • Invossa-K Inj (Invossa-K) The marketed version of TG-C in South Korea, approved by the Korea Ministry of Food and Drug Safety (MFDS) in July 2017 for knee osteoarthritis. Commercialized by Kolon Life Science with marketing support from Mundipharma and Kolon Pharmaceuticals. Asia rights are licensed from Kolon TissueGene.
  • TG-B (TissueGene-B) A pipeline product candidate in TissueGene's portfolio for bone regeneration, part of the company's broader portfolio of cell therapy programs for orthopedic disease treatment alongside TG-C, TG-D, and TG-N.
  • TG-D (TissueGene-D) A pipeline product candidate in TissueGene's portfolio for disc regeneration, being developed for treatment of intervertebral disc disorders as part of the company's orthobiology portfolio of cell and gene therapies.
  • TG-N (TissueGene-N) A pipeline product candidate in TissueGene's portfolio for nerve tissue regeneration, part of the company's four-product portfolio of cell-mediated therapies targeting various orthopedic diseases.

Quantifiable outcome

  • VAS pain score reduction: -18.4 (BMI<30), -26.1 (BMI≥30) in Phase 2 trial
  • +4 more outcomes

Companies that use TissueGene

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

TissueGene technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

TissueGene partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • LonzacoreOEM/ Whitelabel/ Licensing Partner · 1 October 2024Commercial manufacturing partnership signed October 2024. Lonza, the world's largest pharmaceutical CDMO, will produce TG-C for commercial supply. Collaboration with Kolon Biologics (subsidiary of Kolon Life Science) for manufacturing.
  • Kolon Life Science (Middle East Expansion)minorChannel Partner/ Reseller/ Distributor · 22 June 2018Saudi Arabia and UAE added to license agreement with Kolon Life Science until 2024. Consideration for continued presence following FDA approval.
  • Kolon Life SciencecoreChannel Partner/ Reseller/ Distributor · 1 July 2017Kolon Life Science (KOSDAQ: 102940), a subsidiary of Kolon Group, is the exclusive licensee for Asia commercialization of TG-C. Received Korean MFDS marketing approval in July 2017 for Invossa-K Inj. Also partnered with Mitsubishi Tanabe for Japanese market. Kolon Life Science is responsible for manufacturing activities in Asia.
  • Mitsubishi Tanabe PharmacoreChannel Partner/ Reseller/ Distributor · 1 November 2016Exclusive licensing and development agreement for Japan market. Mitsubishi Tanabe paid approximately $24 million upfront plus up to $410 million in development, regulatory, and commercial milestones, plus double-digit sales royalties. Japan OA market forecast: 25 million+ patients aged 40+.
  • Juniper TherapeuticsminorStrategic or Co-development Partner · 1 November 2016Singapore-based Juniper Therapeutics entered technology transfer agreement with Kolon Life Science for Japan development and commercialization of TG-C in 2022.
  • MEDPACEminorImplementation/ SI/ Consulting PartnerClinical operation network partner for Phase 3 clinical trials providing clinical trial management services.
  • ChondrometricsminorImplementation/ SI/ Consulting PartnerClinical operation network partner providing MRI analysis services for clinical trials.
  • Nordic BioscienceminorImplementation/ SI/ Consulting PartnerClinical operation network partner for biomarker analysis in clinical trials.
  • Boston Imaging Core LabminorImplementation/ SI/ Consulting PartnerClinical operation network partner for imaging core laboratory services.
  • ClinMatrixminorImplementation/ SI/ Consulting PartnerClinical operation network partner for clinical data management.
  • Molecular Pathology + GENEUITYminorImplementation/ SI/ Consulting PartnerClinical operation network partner for pathology services.
  • CLARIOminorImplementation/ SI/ Consulting PartnerClinical operation network partner for endpoint adjudication services.
  • LabcorpminorImplementation/ SI/ Consulting PartnerClinical operation network partner for laboratory testing services in clinical trials.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

TissueGene competitors and assessment

Company assessment

Direct peers

  • Flexion Therapeutics: Developer of Zilretta (intra-articular extended-release corticosteroid) for knee osteoarthritis pain. Most direct US commercial-stage peer to TG-C, targeting the same orthopedic/rheumatology prescribers for knee OA pain management.
  • Bioventus: Orthobiologics company offering hyaluronic acid (Durolane, Supartz) and other joint-pain therapies. Directly competes in the knee OA intra-articular injection market with TG-C and shares the same orthopedic surgeon call point.
  • Anika Therapeutics: Developer of viscosupplementation products (Monovisc, Orthovisc, Cingal) for joint pain and early-stage regenerative cartilage repair programs. Same intra-articular OA injection category and similar specialty distribution model.
  • Vericel: Commercial-stage cell-therapy company selling MACI (autologous cultured chondrocytes for cartilage repair). Closest US-listed peer in orthopedic regenerative cell therapy and shares TG-C's orthopedics/sports-medicine surgeon customer base.
  • Mesoblast: Allogeneic mesenchymal stem cell therapy developer with remestemcel-L and pipeline programs targeting inflammatory/orthopedic indications. Comparable cell-therapy platform business model and similar regulatory pathway for biologics in musculoskeletal disease.

Broad incumbents

  • Stryker: Global orthopedic devices leader with a significant orthobiologics franchise and joint-replacement franchise. Relevant incumbent competitor covering both the conservative-care (biologics) and surgical (TKA) ends of the knee OA treatment spectrum.
  • Zimmer Biomet: Major orthopedic reconstruction and sports medicine company with a broad portfolio including knee implants and orthobiologics. Represents the surgical alternative TG-C aims to delay, making it a critical incumbent context.
  • Smith+Nephew: Global medical device company with sports medicine, orthobiologics (Regeneten, Arthroscopic HA products), and knee-reconstruction franchises. Overlaps with TG-C's orthopedic surgeon call point across the conservative-to-surgical spectrum.
  • Sanofi (Genzyme – Synvisc): Synvisc/ Synvisc-One is one of the most-prescribed HA intra-articular injections for knee OA globally, distributed through Genzyme/Sanofi's specialty channel. Represents the dominant incumbent therapy TG-C would displace in the same indication and same prescriber base.

Regional players

  • Seikagaku: Japan-based specialty company focused on hyaluronic acid intra-articular injections (Artz, Supartz) for knee OA. Closest regional comparable in Japan given Kolon's Mitsubishi Tanabe partnership and shares the intra-articular OA injection modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights8 records

Customer concentration

TissueGene social profiles

Digital presence

TissueGene financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TissueGene leadership team

Management profile

Number of profiles

Profiles6 records

TissueGene funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TissueGene M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TissueGene

What does TissueGene do?

TissueGene (Kolon TissueGene, Inc.) develops TG-C (TissueGene-C / Invossa), an allogeneic cell and gene therapy for osteoarthritis of the knee, administered as a single intra-articular injection. The therapy combines non-modified chondrocytes with gene-modified human cells (kidney-derived 293 cells) engineered to express TGF-beta1, aimed at cartilage regeneration, pain reduction, and disease progression delay. The company is also expanding TG-C into hip osteoarthritis and degenerative disc disease indications, with additional pipeline candidates (TG-B, TG-D, TG-N) for bone, disc, and nerve regeneration.

Is TissueGene a public or private company?

TissueGene is a public company. It is classified as public and is currently operating.

When was TissueGene founded?

TissueGene was founded in 1999. It employs 51 to 100 people.

Where is TissueGene based?

TissueGene is headquartered in Rockville, United States, in the North America region.

How does TissueGene make money?

Three revenue lines are on record. Product Sales (US, Europe, South America) is the primary driver. The others are licensing Royalties (Asia) and milestone Payments.

Who are TissueGene's main competitors?

Direct peers on record are Flexion Therapeutics, Bioventus, Anika Therapeutics, Vericel and Mesoblast. Broad incumbents are Stryker, Zimmer Biomet, Smith+Nephew and Sanofi (Genzyme – Synvisc). Seikagaku is listed as a regional player.

Does TissueGene have an API?

No public API is recorded for TissueGene.

What industry is TissueGene in?

TissueGene's product category is Cell and Gene Therapy. Its primary akta.pro industry code is HLAIAAAO, Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies), with a secondary code of HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewKolon TissueGene: Derivative gains lifted reported profit as TG-C knee OA trials advanced toward BLA discussionsKolon TissueGene reported $9 million revenue and a $16.669 million operating loss, with $50.072 million net income from derivative gains and an insurance recovery. Its TG-C knee OA Phase 3 follow-up and analysis continue after July topline data for one pivotal study.NateKorea Tissue Gene's CEO Noh Moon-jong resigns... Seung-ho Jeon to lead alone: Nate NewsKolon TissueGene CEO Noh Moon-jong resigned for personal reasons, effective July 17, and Jeon Seung-ho became sole CEO. The company announced U.S. Phase 3 results for TG-C, showing no statistically significant difference in primary efficacy, and plans additional analysis and a second trial.Nate'TG-C 30-year witness' Nomun Jong, CEO of Kolon TissueGene, resigns... Two months after the failure of the Phase 3 trial in the U.S.: Nate NewsNo Mun-jong, co-CEO of Kolon TissueGene, resigned as CEO on August 18, citing personal reasons, two months after TG-C's first U.S. Phase 3 trial failed to show statistical significance. The company will now be led by Jeon Seung-ho, with the second Phase 3 trial rescheduled for December.American City Business JournalsKolon TissueGene cuts two-thirds of workers after clinical trial failsKolon TissueGene has laid off nearly two-thirds of its workforce following the failure of a clinical trial for its osteoarthritis drug, which showed no improvement in knee pain or function. The termination of this significant portion of staff reflects the company's response to the negative clinical outcomes.FierceBiotechKolon TissueGene shrinks workforce after pivotal osteoarthritis trial missKolon TissueGene is laying off 37 employees at its Maryland headquarters following a phase 3 trial for its osteoarthritis therapy TG-C that missed its primary endpoints. The company described the workforce reduction as part of a broader operational realignment while it awaits topline results from a second phase 3 trial in October.GlobalnewstopKolon TissueGene FIs Face Potential Losses on $83 Million Convertible Bond Investment < Venture Capital < The Vista < ArticleKolon TissueGene's fourth-series convertible bonds, totaling $83.3 million, are facing losses after the company's share price fell 90% following a failed Phase 3 trial for TG-C. Investors, including Stonebridge and STIC, remain underwater with conversion rights locked until September 2027, and the company's liquidity may be insufficient to repay if put options are exercised.NateConcerns about the extinction of KOSDAQ due to the concentration of single-item leverage: Nate NewsThe KOSDAQ market index has fallen to 790.28, down approximately 21% from its 2004 baseline, as capital has shifted away from KOSDAQ into single-stock leverage and inverse products tied to Samsung Electronics and SK Hynix, with daily trading volume on KOSDAQ declining from 15 trillion won to 6 trillion won since May 27. Financial authorities announced countermeasures on July 16 including raising minimum deposits to 30 million won and minimum trading units to 20 lots, but trading volumes showed no significant change, with skepticism growing over whether these measures will reverse the capital outflow. The downturn has been compounded by poor performance in KOSDAQ's core bio/pharmaceutical sector, where companies like Kolon TissueGenesis, Samchundang Pharma, and HLB suffered significant stock declines due to clinical trial failures and regulatory setbacks.BioWorldKolon Tissuegene shares fall as TG-C misses knee OA endpointsKolon Tissuegene's TG-C, an allogeneic cell and gene therapy for knee osteoarthritis, missed both co-primary endpoints and all key secondary endpoints in a phase III trial. The top-line readout was highly anticipated, and the company's shares fell as a result.NateThe 'growing pains' of Kolon TissueGene... Confusion over data as TG-C's Phase 3 in the US is halted [The Gate Bio]: Nate NewsKolon TissueGene's osteoarthritis therapy TG-C failed to meet the primary endpoint in the first trial of its US Phase 3 study, with treated patients showing no statistically significant improvement over the placebo group in pain (VAS) and joint function (WOMAC) scores after 12 months. The company attributed the outcome to a larger-than-expected placebo effect lasting 24 months and said a second Phase 3 trial would be analyzed differently, with results expected in October. The company also faced scrutiny for posting inconsistent figures across its Financial Supervisory Service announcement, press release, and press conference materials, raising concerns about data management practices for a treatment that previously had its South Korean approval revoked in 2019 over cell identity issues.Nate[Featured Stock] Kolon TissueGene, Hits Lower Limit for Two Consecutive Days After U.S. Phase 3 Clinical Trial Aftershock: Nate NewsKolon TissueGene's stock hit the daily price limit for a second consecutive day on July 22 after the company disclosed that its U.S. Phase 3 clinical trial for osteoarthritis treatment TG-C failed to achieve statistical significance on the co-primary endpoint. While the TG-C group demonstrated pain relief and joint function improvement comparable to or better than previous trials, the placebo group showed similarly strong improvements that negated the statistical significance of results. CEO Roh Moon-jong attributed the unusually prolonged placebo effect—lasting up to 24 months versus the typical 3-6 months—to the disappointing outcome.